commun
respiratori
virus
respiratori
syncyti
viru
rsv
influenza
virus
parainfluenza
virus
adenovirus
picornavirus
import
caus
respiratori
diseas
immunocompromis
adult
cancer
recent
studi
demonstr
minimum
adult
bone
marrow
transplant
bmt
recipi
adult
leukemia
hospit
acut
respiratori
ill
commun
respiratori
viru
infect
tempor
occurr
infect
immunocompromis
patient
tend
mirror
occurr
commun
clinic
ill
rang
selflimit
upper
respiratori
ill
fatal
pneumonia
depend
type
viru
type
degre
immunosuppress
pneumonia
may
viral
bacterialfung
mix
highest
frequenc
progress
fatal
viral
pneumonia
report
rsv
infect
recent
transplant
bmt
recipi
myelosuppress
patient
leukemia
studi
suggest
earli
therapi
rsv
pneumonia
combin
aerosol
ribavirin
intraven
immunoglobulin
may
benefit
defin
effect
prophylact
therapeut
strategi
challeng
given
divers
virus
wide
spectrum
immunocompromis
patient
vari
vulner
seriou
commun
respiratori
viru
diseas
frequent
presenc
opportunist
infect
medic
problem
combin
antivir
drug
immunotherapi
may
need
consid
potenti
addit
effect
well
prevent
emerg
resist
viru
occur
monotherapi
influenza
amantadin
rimantadin
optim
therapi
need
defin
control
trial
howev
appear
favor
respons
hing
initi
therapi
earli
stage
respiratori
ill
ver
past
decad
grow
recognit
commun
respiratori
virus
respiratori
syncyti
viru
rsv
influenza
virus
parainfluenza
virus
adenovirus
picornavirus
frequent
caus
seriou
respiratori
diseas
among
immunocompromis
patient
cancer
emerg
virus
set
grow
popul
sever
immunodefici
patient
coupl
emerg
knowledg
frequenc
serious
commun
respiratori
viru
infect
immunocompromis
patient
gener
prior
commun
respiratori
viru
infect
uncommonli
diagnos
anderson
cancer
center
mdacc
similar
cancer
center
respiratori
viral
diseas
attribut
primarili
herpesvirus
particularli
cytomegaloviru
cmv
occasion
adenovirus
time
intens
surveil
program
initi
collabor
acut
viral
respiratori
diseas
unit
baylor
colleg
medicin
soon
becam
appar
commun
respiratori
virus
frequent
caus
acut
upper
well
lower
respiratori
tract
diseas
among
immunocompromis
adult
cancer
two
consecut
winter
season
novemb
may
novemb
may
commun
respiratori
viru
infect
diagnos
adult
bone
marrow
transplant
bmt
recipi
hospit
mdacc
acut
respiratori
ill
minimum
estim
frequenc
infect
sinc
case
confirm
cultur
rather
antigen
detect
serolog
perform
infect
due
rsv
influenza
virus
picornavirus
parainfluenza
virus
adenovirus
differ
virus
intermingl
two
wintertim
period
commun
interven
warmer
month
rsv
fluenza
disappear
hospit
commun
patient
commun
respiratori
viru
infect
young
middleag
adult
age
group
virus
would
typic
caus
rel
benign
selflimit
ill
infect
acquir
autolog
n
well
allogen
n
transplant
recipi
preengraft
n
well
postengraft
n
patient
howev
sever
infect
particularli
rsv
tempor
relat
time
transplant
sever
infect
tend
occur
frequent
earli
posttranspl
period
earli
year
surveil
studi
infect
acquir
nosocomi
number
nosocomi
infect
sinc
declin
consider
aggress
multifacet
infectioncontrol
strategi
one
infect
acquir
protect
environ
confirm
infect
primarili
reflect
reactiv
latent
viru
case
herpesvirus
acquir
exogen
patient
ill
remain
limit
upper
respiratori
tract
character
rhinorrhea
nasal
sinu
congest
sore
throat
andor
cough
none
patient
die
patient
ill
complic
pneumonia
either
primari
viral
secondari
bacterialfung
pneumonia
overal
mortal
rate
associ
pneumonia
high
among
autolog
well
allogen
bmt
recipi
contrast
pneumonia
attribut
cmv
pneumocysti
carinii
fungi
pneumonia
preced
upper
respiratori
ill
autopsi
perform
patient
die
patient
rsv
document
extens
rsv
pneumonia
histopatholog
immunohistochemistri
one
also
candida
pneumonia
two
three
patient
influenza
histopatholog
consist
viral
pneumonia
pathogen
identifi
patient
picornaviru
thu
autopsi
examin
confirm
pulmonari
invas
commun
respiratori
virus
adult
bmt
recipi
era
reason
effect
prophylaxi
cmv
diseas
commun
respiratori
virus
assum
domin
role
etiolog
viral
pneumonia
adult
bmt
recipi
tabl
two
wintertim
period
pneumonia
associ
commun
respiratori
virus
occur
four
time
frequent
associ
cmv
vs
respect
overal
mortal
attribut
pneumonia
associ
commun
respiratori
virus
four
time
high
attribut
pneumonia
associ
cmv
vs
respect
commun
respiratori
virus
also
frequent
caus
acut
upper
lower
respiratori
tract
diseas
among
hospit
adult
leukemia
period
novemb
may
commun
respiratori
viru
infect
document
cultur
adult
leukemia
hospit
mdacc
acut
respiratori
ill
underli
diseas
acut
myelogen
leukemia
n
acut
lymphocyt
leukemia
n
chronic
myelogen
leukemia
n
chronic
lymphocyt
leukemia
n
leukemia
n
infect
due
influenza
virus
rsv
picornavirus
parainfluenza
virus
adenovirus
multipl
commun
respiratori
virus
total
infect
acquir
nosocomi
similar
transplant
patient
tempor
occurr
infect
reflect
occurr
commun
infect
due
rsv
influenza
occur
cooler
month
year
wherea
infect
due
parainfluenza
virus
adenovirus
picornavirus
occur
year
round
patient
ill
remain
confin
upper
respiratori
tract
character
rhinorrhea
nasal
sinu
congest
sore
throat
andor
cough
none
patient
die
similar
transplant
popul
infect
complic
pneumonia
associ
mortal
pneumonia
could
distinguish
major
preced
upper
respiratori
ill
autopsi
perform
patient
leukemia
die
case
histopatholog
reveal
viral
inclus
andor
syncyti
cell
confirm
diagnosi
viral
pneumonia
seventh
patient
influenza
cultur
lung
tissu
eighth
patient
diffus
nonspecif
fibrot
pneumon
three
patient
concurr
fungal
pneumonia
signific
morbid
mortal
associ
commun
respiratori
viru
infect
patient
leukemia
make
clear
problem
uniqu
patient
extrem
global
immunodefici
allogen
bmt
recipi
commun
respiratori
virus
associ
seriou
pneumonia
broader
group
patient
patient
popul
risk
need
identifi
commun
respiratori
virus
rsv
receiv
attent
associ
except
high
frequenc
fatal
viral
pneumonia
certain
subset
patient
among
immunocompromis
adult
sporad
case
rsv
diseas
report
englund
et
al
describ
seriou
rsv
diseas
immunocompromis
adult
studi
togeth
subsequ
studi
bmt
recipi
univers
minnesota
fred
hutchinson
cancer
research
center
fhcrc
center
establish
sever
salient
featur
diseas
rsv
capabl
caus
seriou
pneumonia
adult
bmt
recipi
frequent
commun
outbreak
rsv
infect
adult
bmt
recipi
follow
clinic
sequenc
children
upper
respiratori
ill
preced
pneumonia
frequenc
progress
pneumonia
highest
preengraft
transplant
recipi
howev
mortal
associ
pneumonia
similarli
high
preand
postengraft
patient
aerosol
ribavirin
alon
appear
benefit
start
prior
onset
pneumonia
start
onset
pneumonia
mortal
rate
therapeut
trial
combin
antivir
therapi
immunotherapi
rsv
pneumonia
initi
mdacc
previou
studi
suggest
aerosol
ribavirin
alon
effect
promis
report
potenti
benefici
effect
immunoprophylaxi
well
immunotherapi
rsv
infect
vitro
anim
studi
children
therapi
consist
aerosol
ribavirin
mgml
h
day
intraven
immunoglobulin
iv
ig
mg
kg
everi
day
first
year
studi
select
lot
iv
ig
chosen
contain
substanti
rsv
microneutr
antibodi
titer
rsv
subtyp
novemb
novemb
rsv
infect
diagnos
cultur
autopsi
hospit
adult
bmt
recipi
case
occur
wintertim
period
account
signific
proport
respiratori
ill
occur
among
hospit
adult
bmt
recipi
respect
declin
frequenc
infect
second
third
year
attribut
primarili
aggress
infectioncontrol
strategi
new
polici
postpon
transplant
patient
upper
respiratori
ill
patient
present
upper
respiratori
ill
pneumonia
develop
patient
tabl
ii
mortal
rate
among
patient
pneumonia
combin
therapi
initi
hour
prior
respiratori
failur
requir
mechan
ventil
n
contrast
mortal
rate
among
patient
treat
onset
respiratori
failur
n
patient
treat
n
one
patient
treat
highdos
shortdur
aerosol
ribavirin
center
tri
treatment
regimen
vari
success
includ
combin
aerosol
intraven
ribavirin
rel
eas
administr
intraven
ribavirin
attract
howev
recent
trial
mortal
rate
among
bmt
recipi
rsv
pneumonia
treat
intraven
ribavirin
dose
ribavirin
use
studi
consider
lower
use
treat
hemorrhag
fever
rais
question
whether
higher
dose
might
benefit
earlier
stage
respiratori
ill
sinc
respons
therapi
vari
consider
depend
stage
respiratori
ill
well
type
degre
durat
underli
immunodefici
optim
therapi
need
defin
control
trial
risk
pneumonia
death
close
relat
time
transplant
tabl
iii
year
rsv
infect
document
viral
cultur
autopsi
adult
bmt
recipi
inpati
outpati
sixteen
patient
month
posttranspl
develop
pneumonia
minimum
estim
sinc
patient
upper
respiratori
ill
month
posttranspl
treat
preemptiv
combin
aerosol
ribavirin
iv
ig
patient
may
develop
pneumonia
treat
contrast
patient
month
posttranspl
develop
pneumonia
die
patient
relaps
leukemia
profound
chemotherapyinduc
myelosuppress
sever
strike
similar
outcom
respons
therapi
rsv
pneumonia
aerosol
ribavirin
iv
ig
outcom
respons
therapi
cmv
pneumonia
ganciclovir
iv
ig
tabl
iv
spite
intens
surveil
system
rsv
cmv
diseas
viral
pneumonia
diagnos
onset
respiratori
failur
death
result
mortal
rate
approach
even
therapi
initi
onset
respiratori
failur
mortal
rate
associ
rsv
cmv
pneumonia
high
respect
high
overal
mortal
rate
viral
pneumonia
rsv
pneumonia
cmv
pneumonia
approach
rsv
diseas
probabl
need
model
strategi
work
cmv
diseas
name
prophylaxi
preemptiv
therapi
earli
stage
viral
ill
rsv
diseas
preemptiv
therapi
requir
treat
highrisk
patient
upper
respiratori
ill
three
wintertim
period
studi
mdacc
preemptiv
therapi
combin
aerosol
ribavirin
iv
ig
mgkg
everi
day
administ
bmt
recipi
upper
respiratori
ill
tabl
v
aerosol
ribavirin
administ
dose
mg
ml
hday
patient
dose
mg
ml
hour
everi
hour
patient
patient
ill
remain
confin
upper
respiratori
tract
patient
surviv
patient
autolog
bmt
recipi
die
rsv
pneumonia
one
patient
die
prolong
marrow
aplasia
due
graft
failur
develop
progress
rsv
pneumonia
receiv
hday
regimen
pa
tient
die
complet
resolut
respiratori
ill
hday
regimen
discharg
home
return
month
later
fulmin
rsv
pneumonia
subsequ
die
clear
repres
relaps
infect
reinfect
control
clinic
trial
need
evalu
optim
preemptiv
therapi
epidemiolog
clinic
cours
respons
therapi
rsv
infect
adult
leukemia
mirror
find
adult
bmt
recipi
novemb
novemb
rsv
document
cultur
adult
leukemia
care
mdacc
case
occur
winter
month
rsv
preval
commun
transplant
recipi
onset
ill
character
upper
respiratori
ill
patient
frequenc
progress
pneumonia
consider
higher
among
myelosuppress
absolut
neutrophil
among
nonmyelosuppress
patient
higher
among
recent
transplant
myelosuppress
bmt
recipi
thu
upper
respiratori
ill
complic
pneumonia
patient
myelosuppress
compar
patient
myelosuppress
mortal
rate
associ
pneumonia
set
myelosuppress
high
contrast
none
nonmyelosuppress
patient
die
prompt
therapi
rsv
pneumonia
aerosol
ribavirin
mgml
hday
iv
ig
earli
stage
pneumonia
associ
favor
outcom
tabl
ii
none
patient
therapi
initi
hour
prior
intub
die
patient
myelosuppress
contrast
mortal
rate
among
patient
receiv
therapi
n
patient
began
therapi
onset
respiratori
failur
n
patient
unabl
toler
therapi
n
autopsi
perform
adult
leukemia
bmt
recipi
die
rsv
pneumonia
case
histopatholog
immunohistochem
studi
confirm
diagnosi
invas
rsv
pneumonia
three
patient
also
pulmonari
pathogen
summari
rsv
frequent
caus
lifethreaten
pneumonia
subset
adult
leukemia
bmt
recipi
highrisk
patient
need
identifi
optim
therapi
rout
administr
need
defin
control
trial
appear
favor
respons
hing
initi
therapi
earli
stage
pneumonia
subset
patient
high
frequenc
progress
pneumonia
preemptiv
therapi
upper
respiratori
ill
need
consid
simplest
effect
therapi
prevent
infectioncontrol
measur
postpon
dosemodif
chemotherapi
feasibl
highrisk
patient
rsv
upper
respiratori
ill
whether
prophylact
hightit
rsv
immunoglobulin
benefit
patient
young
children
need
studi
influenza
consid
one
import
respiratori
diseas
mankind
center
diseas
control
long
recommend
immunocompromis
patient
receiv
annual
influenza
vaccin
chemoprophylaxi
amantadinerimantadin
influenza
season
uncommon
practic
cancer
center
part
skeptic
sever
immunocompromis
patient
abl
mount
protect
antibodi
respons
activ
immun
part
pauciti
data
document
morbid
mortal
influenza
patient
sinc
activ
look
influenza
part
gener
surveil
commun
respiratori
virus
similar
rsv
occurr
influenza
hospit
immunocompromis
adult
mirror
occurr
influenza
commun
three
wintertim
period
last
week
influenza
document
cultur
approxim
adult
leukemia
bmt
recipi
hospit
mdacc
acut
respiratori
ill
closer
evalu
adult
leukemia
adult
bmt
recipi
cultureconfirm
influenza
hospit
mdacc
three
winter
outbreak
reveal
ill
associ
signific
morbid
mortal
clinic
cours
influenza
similar
two
subset
patient
tabl
vi
overal
ill
complic
pneumonia
patient
pneumoniaassoci
mortal
rate
although
mortal
rate
dramat
high
rsv
pneumonia
nonetheless
high
high
frequenc
pulmonari
complic
death
highlight
need
aggress
prophylact
strategi
autopsi
examin
patient
die
influenza
reveal
histopatholog
consist
viral
pneumonia
patient
also
pulmonari
pathogen
patient
autopsi
perform
bacteri
fungal
pneumonia
although
influenza
studi
global
decad
guidelin
treatment
influenza
pneumonia
known
whether
amantadinerimantadin
prevent
progress
uncompl
influenza
pneumonia
immunocompromis
patient
studi
suggest
amantadinerimantadin
andor
ribavirin
aerosol
intraven
may
benefit
studi
mani
patient
treat
amantadinerimantadin
patient
also
receiv
ribavirin
howev
done
systemat
manner
part
inabl
diagnos
ill
time
manner
efficaci
therapi
could
evalu
nevertheless
sever
import
find
emerg
similar
viral
pneumonia
caus
rsv
cmv
antivir
therapi
benefit
initi
onset
respiratori
failur
also
similar
immunocompet
patient
signific
proport
immunocompromis
patient
treat
amantadinerimantadin
alon
develop
resist
strain
viru
suggest
amantadinerimantadin
alon
may
option
therapi
influenza
patient
effect
therapeut
regimen
influenza
viru
pneumonia
need
establish
immunocompet
well
immunocompromis
patient
combin
antivir
drug
rimantadin
ribavirin
andor
neuraminidas
inhibitor
need
investig
well
potenti
addit
benefit
immunotherapi
report
influenza
immunocompromis
adult
document
high
frequenc
pulmonari
complic
death
wide
spectrum
observ
probabl
reflect
wide
spectrum
immunocompromis
patient
studi
morbid
mortal
influenza
well
commun
respiratori
virus
appear
relat
type
degre
durat
immunosuppress
less
immunocompromis
patient
clinic
cours
influenza
may
compar
immunocompet
person
also
noteworthi
unlik
rsv
influenza
virus
undergo
frequent
antigen
variat
preval
type
serotyp
vari
morbid
mortal
may
expect
vari
year
year
parainfluenza
virus
rare
caus
selflimit
upper
respiratori
ill
adult
import
parainfluenza
virus
caus
lifethreaten
pneumonia
sever
immunocompromis
adult
highlight
two
studi
univers
minnesota
mdacc
earli
describ
adult
bmt
recipi
respect
epidemiolog
frequenc
clinic
cours
adult
bmt
recipi
cultureconfirm
parainfluenza
viru
infect
care
mdacc
period
januari
septemb
recent
review
overal
frequenc
infect
similar
frequenc
note
univers
minnesota
studi
although
infect
occur
throughout
year
case
occur
spring
summer
half
case
occur
spring
summer
highlight
need
anticip
outbreak
infect
outbreak
period
parainfluenza
virus
isol
one
third
adult
bmt
recipi
hospit
acut
respiratori
ill
clinic
cours
outcom
parainfluenza
viru
infect
among
hospit
patient
leukemia
mirror
experi
hospit
bmt
recipi
among
consecut
bmt
recipi
consecut
patient
leukemia
myelosuppress
hospit
parainfluenza
viru
infect
ill
complic
pneumonia
case
respect
pneumonia
preced
upper
respiratori
ill
overal
mortal
rate
pneumonia
high
respect
autopsi
examin
patient
reveal
histopatholog
consist
viral
pneumonia
patient
diffus
fibrot
pneumon
seventh
patient
four
patient
seriou
concurr
opportunist
infect
find
highlight
profound
immunodefici
patient
establish
therapi
parainfluenza
viru
infect
vitro
data
anecdot
report
suggest
ribavirin
may
benefit
univers
minnesota
studi
patient
treat
aerosol
ribavirin
without
appar
benefit
studi
bmt
recipi
pneumonia
treat
promptli
combin
aerosol
ribavirin
iv
ig
surviv
tabl
vii
howev
patient
surviv
without
antivir
therapi
suggest
mani
pneumonia
selflimit
viral
pneumonia
andor
bacteri
fungal
superinfect
signific
number
pneumonia
resolv
antibacterialantifung
therapi
alon
well
high
frequenc
concurr
opportunist
infect
may
mask
potenti
benefit
therapi
make
clear
therapeut
trial
parainfluenza
virusassoci
pneumonia
need
control
therapeut
trial
also
requir
routin
avail
rapid
diagnost
test
parainfluenza
viru
current
avail
rsv
sinc
cultur
result
frequent
becom
avail
onset
respiratori
failur
adenovirus
extens
studi
commun
respiratori
viru
immunocompromis
patient
adenovirus
distinguish
commun
respiratori
virus
dna
rather
rna
virus
thought
acquir
endogen
reactiv
well
exogen
adenovirus
typic
caus
wide
rang
clinic
syndrom
includ
respiratori
tract
diseas
urinari
tract
diseas
enterocol
hepat
enceph
dissemin
diseas
march
may
adenovirus
cultur
respiratori
tract
adult
bmt
recipi
care
mdacc
fifteen
patient
surviv
includ
patient
upper
respiratori
ill
patient
pneumonia
one
treat
intraven
ribavirin
thirteen
patient
die
includ
patient
pneumonia
patient
dissemin
diseas
major
pneumonia
preced
upper
respiratori
ill
seven
patient
die
treat
intraven
ribavirin
without
appar
benefit
howev
case
therapi
initi
onset
dissemin
diseas
multiorgan
failur
risk
factor
fatal
diseas
includ
isol
adenoviru
multipl
site
prolong
shed
risk
factor
need
identifi
rapid
diagnost
test
need
develop
patient
recogn
earli
potenti
therapi
optim
therapi
need
defin
includ
role
immunoglobulin
adopt
immunotherapi
donor
leukocyt
understand
role
picornavirus
rhinovirus
enterovirus
immunocompromis
patient
minim
sinc
picornaviru
infect
identifi
among
adult
leukemia
bmt
recipi
isol
test
thu
far
rhinovirus
major
patient
ill
limit
upper
respiratori
tract
complic
pneumonia
appear
bacteri
fungal
origin
howev
patient
clinic
cours
consist
viral
pneumonia
die
unexplain
interstiti
pneumonia
analysi
experi
way
coronavirus
one
frequent
caus
acut
respiratori
ill
commun
difficult
isol
clinic
specimen
systemat
look
immunocompromis
patient
immunocompromis
patient
live
protect
island
part
commun
suscept
respiratori
viral
infect
frequent
afflict
member
commun
subset
immunocompromis
patient
commonplac
otherwis
trivial
ill
may
associ
seriou
morbid
mortal
virus
limit
mean
identifi
infect
time
clinic
use
manner
almost
guidelin
effect
prevent
treatment
addit
therapeut
option
choos
efficaci
establish
larg
number
patient
serious
ill
diseas
effect
prophylact
therapeut
regimen
need
defin
challeng
sinc
wide
divers
virus
need
approach
individu
wide
rang
immunocompromis
patient
vari
vulner
seriou
commun
respiratori
viru
diseas
even
within
particular
subset
patient
leukemia
patient
bmt
recipi
wide
rang
vulner
seriou
diseas
often
state
flux
reflect
worsen
improv
immunodefici
confound
clinic
pictur
frequent
presenc
seriou
opportunist
infect
medic
problem
conduct
control
trial
need
defin
effect
prophylact
therapeut
regimen
mani
complex
problem
need
address
collabor
multipl
medic
center
care
patient
